Latest News

FDA Fast Tracks IDP-023 for Non-Hodgkin Lymphoma and Myeloma
FDA Fast Tracks IDP-023 for Non-Hodgkin Lymphoma and Myeloma

February 29th 2024

The natural killer cell therapy IDP-023 is being studied in a phase 1 trial for the treatment of patients with non-Hodgkin lymphoma and multiple myeloma.

Acalabrutinib With Axi-Cel Shows Promising Responses in R/R B-Cell Lymphoma
Acalabrutinib With Axi-Cel Shows Promising Responses in R/R B-Cell Lymphoma

February 23rd 2024

What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL
What is the Best Dose of Lenalidomide? Lunning Provides His Analysis in R/R DLBCL

February 16th 2024

Denileukin Diftitox BLA Resubmitted for CTCL After Addressing FDA Concerns
Denileukin Diftitox BLA Resubmitted for CTCL After Addressing FDA Concerns

February 14th 2024

Soquelitinib Receives FDA Orphan Drug Designation for T-Cell Lymphomas
Soquelitinib Receives FDA Orphan Drug Designation for T-Cell Lymphomas

February 12th 2024

More News